Can vitamin a derivative shield immune system during cancer radiation?
NCT ID NCT06439888
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a drug called ATRA (a form of vitamin A) to standard radiation therapy can prevent a drop in infection-fighting white blood cells in people with a few metastatic tumors. About 58 adults with solid cancers that have spread to up to 5 spots will receive radiation to all visible tumors, with or without ATRA pills taken for 3 days every 3 weeks. The goal is to see if the combination is safe and reduces the risk of low lymphocyte counts, which can weaken the immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
all-trans retinoic acid (ATRA, also known as tretinoin) plus stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this approach could reduce a common side effect of radiation (low white blood cell counts) and potentially improve cancer control in patients with a few metastatic spots.
What could go wrong
This is an early-phase trial with only 58 participants, so results may not apply broadly. ATRA can cause side effects like skin dryness or headache, and the combination may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Bérard
NOT_YET_RECRUITINGLyon, 69000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Gustave Roussy
RECRUITINGVillejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact